Nucs AI funding news – Medtech Startup Nucs AI has Raised $3.5 Million in Seed Funding

As the number of prostate cancer cases is expected to double by 2040, the company uses advanced AI to find patients who are most likely to benefit from PSMA-targeted treatments.

PSMA-PET/CT imaging is now the standard method for detecting and staging prostate cancer because it is more accurate than traditional imaging. PSMA-targeted treatments use radiation to target cancer cells and can help shrink or slow down tumor growth.

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

The company is creating two products for doctors that use PSMA-targeted imaging and treatments.

DeepPSMA uses AI to quickly and accurately detect, stage, and measure prostate cancer from PSMA-PET/CT images. SelectPSMA predicts how well a patient will respond to PSMA-targeted cancer treatments.

According to Nijat Ahmadov, co-founder and CEO at Nucs AI, the number of radiologists and prostate cancer specialists is not increasing as fast as the number of cases: “AI is the only technology that can close this gap, giving clinicians more time with patients and maintaining, even improving, the standard of care. Our SelectPSMA technology is designed to identify those who will respond to PSMA-targeted radiopharmaceuticals such as 177Lu-PSMA-617 (Pluvicto).”

The company will use the funding to continue developing its platform and to support getting approval from the FDA for its technology in North America.

About Nucs AI

Nucs AI is changing how prostate cancer is managed. Their platform uses artificial intelligence to provide deep insights into tumor lesions, helping both patients and doctors make better decisions with advanced analysis and evidence-based tools.